Clinical trials: BCG
Vaccine Preventable Disease, Measles
Measles and BCG Vaccines for Mother and Child
In Africa, the mortality from infectious diseases remains high. The investigators have discovered that live vaccines such as the BCG vaccine against tuberculosis and the measles vaccine can strengthen resistance to other…
- Conditions
- Vaccine Preventable Disease, Measles, Mother-Infant Interaction, BCG Vaccination Reaction
- Trial name
- MATVAC (NCT04899765)
- Testing
- BCG vaccine, Measles vaccine
- Where
- Guinea-Bissau
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
Tuberculosis Infection
Immunization With BCG Vaccine to Prevent Tuberculosis Infection
The purpose of this research is to find out if a single dose of pre-travel vaccination with BCG can lessen tuberculosis (TB) infection by producing an immune response when given to adults traveling to countries with a high or…
- Trial name
- TIPI (NCT04453293)
- Testing
- BCG (Tokyo 172) vaccine
- Where
- 7 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Side Effect of Drug
NORTH-REG Dwell-Time Study
Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations.
- Trial name
- NCT04701151
- Testing
- Bacillus Calmette Guerin
- Where
- 11 sites in Denmark, Iceland and 1 more
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- Jørgen Bjerggaard Jensen
COVID-19
BCG Vaccination to Prevent COVID-19
The current COVID-19 epidemic threatens to overwhelm the capacity of many countries to meet their populations' health care needs.
- Trial name
- NUEVA (NCT04632537)
- Testing
- Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine, Preservative-free saline
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Tuberculosis
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
This is a human pilot study of 16 healthy BCG-naïve volunteers to quantify BCG from the BCG vaccination site. Volunteers will be vaccinated with BCG.
- Trial name
- NCT00653627
- Testing
- BCG
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Study of MVA85A in Healthy Infants
This was a Phase II double-blinded randomized controlled evaluation of safety, immunogenicity and efficacy of MVA85A/AERAS-485 in Bacillus Calmette-Guérin (BCG) vaccinated infants without tuberculosis or HIV infection.
- Trial name
- NCT00953927
- Testing
- MVA85A/AERAS-485, Candida Skin Test Antigen
- Where
- 3 sites in South Africa
- Volunteers
- 2,797 people, healthy volunteers welcome
- Sponsor
- Aeras
Non-Muscle Invasive Bladder Cancer, HER2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
This is a prospective, open, single-center clinical study of anti-HER2-ADC combined with PD-1 monoclonal antibody for bladder sparing treatment in non-muscular invasive bladder cancer (NMIBC) patients with HER2-expressing.
- Trial name
- NCT05957757
- Testing
- RC48, Tislelizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Covid19, BCG Vaccination Reaction
Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland
Countries that have not carried out universal mass vaccination against tuberculosis (BCG) have been shown to have higher incidence and death rates due to COVID-19 than countries with mass, long-term BCG immunization programmes.
- Conditions
- Covid19, BCG Vaccination Reaction, SARS-CoV Infection
- Trial name
- NCT04648800
- Testing
- BCG-10 vaccine, 0.9% saline
- Where
- 6 sites in Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hanna Czajka
Tuberculosis
Phase I Clinical Protocol of BCG-PPD in Healthy People
A total of 80 healthy people aged 65 years and below who are randomly assigned to the experimental group and the control group. The experimental group is injected with BCG-PPD test drug once, and the control group is injected…
- Trial name
- NCT04593771
- Testing
- BCG-PPD
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Tuberculosis
Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers
The purpose of this study is to evaluate the experimental tuberculosis (TB) vaccine called ID93+GLA-SE. The safety, immunogenicity, and efficacy of ID93+GLA-SE will be compared to placebo, after three intramuscular (IM)…
- Trial name
- NCT03806686
- Testing
- ID93+GLA-SE
- Where
- 3 sites in South Korea
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Quratis Inc.
Tuberculosis
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
The purpose of the study is to develop a BCG challenge model for use in short term Phase I human trials capable of assessing the ability of TB drugs and/or vaccine-induced immune responses to impact in vivo mycobacterial…
- Trial name
- NCT05592223
- Testing
- BCG Vaccine USP, Isoniazid, Rifampin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Covid19, Non-specific Effects of Vaccines
Using BCG to Protect Senior Citizens During the COVID-19 Pandemic
Background: The virus SARS-CoV-2 has spread rapidly throughout the world. Seniors are at high risk of severe COVID-19 when infected.
- Conditions
- Covid19, Non-specific Effects of Vaccines, Heterologous Immunity, Morbidity
- Trial name
- NCT04542330
- Testing
- BCG-Denmark, Saline
- Where
- Denmark
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- Bandim Health Project
COVID-19, Vaccine Reaction
Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction
The COSI BAIR trial will involve approximately 60 children, aged 5 to 8 years old, comprising a subset of participants from the Melbourne Infant Study BCG for Allergy and Infection Reduction (MIS BAIR) randomised controlled…
- Conditions
- COVID-19, Vaccine Reaction, Immunization; Infection
- Trial name
- COSI BAIR (NCT05168709)
- Testing
- Tozinameran
- Where
- Australia
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
COVID
BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots
Rationale: SARS-CoV2 viral infection is spreading rapidly throughout the world and in India the epidemic poses a major threat to the public health system.
- Trial name
- NCT04475302
- Testing
- BCG vaccine (Freeze-dried)
- Where
- India
- Volunteers
- 2,175 people, healthy volunteers welcome
- Sponsor
- Tuberculosis Research Centre, India
Tuberculosis
A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)
This Phase I study will be conducted as a randomized, placebo-controlled, double-blind, dose-escalation study in four groups of healthy adult male and female subjects who are BCG-vaccinated, HIV-negative, and have no evidence of…
- Trial name
- C-011-404 (NCT02109874)
- Testing
- AERAS-404 (mcg H4/nmol IC31), Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl
- Where
- South Africa
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aeras
Whooping Cough
Influence of BCG on TDaP-IPV Vaccination
This study has three purposes: To investigate whether the immune response to pertussis is increased when TDaP-IPV is given together with BCG vaccine, compared to when it is given alone.
- Trial name
- NCT02771782
- Testing
- BCG vaccine (SSI), TDaP-IPV vaccine
- Where
- Netherlands
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Tuberculosis
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A
This is a Phase I study whose primary outcome is to assess the safety of a new tuberculosis vaccine, FP85A, when administered individually and sequentially with MVA85A in a prime-boost regime, to healthy volunteers, who have…
- Trial name
- NCT00653770
- Testing
- FP85A, MVA85A
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Tuberculosis
A Study of MVA85A in Healthy Children and Infants
This study is designed to evaluate the safety of the TB vaccine MVA85A in healthy children and infants in South Africa. A single vaccination with MVA85A has been shown to be safe and highly immunogenic in a wide range of subjects…
- Trial name
- NCT00679159
- Testing
- MVA85A, Prevenar
- Where
- South Africa
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Severe Illness, Septicaemia
Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda
BCG vaccination may have non-specific effects (NSE) i.e., additional benefits on childhood morbidity and mortality that are separate the vaccine's effect on the incidence of disseminated tuberculosis.
- Conditions
- Severe Illness, Septicaemia, Diarrhoea, Lower Respiratory Infection
- Trial name
- NCT02606526
- Testing
- BCG at birth, Control arm: Delayed BCG
- Where
- Uganda
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Makerere University
Tuberculosis
Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe
The study is designed to test the hypothesis that BCG administration via jet injector will produce a comparable immune response and that there will be no significant differences in safety or reactogenicity between BCG…
- Trial name
- NCT01742364
- Testing
- Bioject ID Pen, Needle and syringe
- Where
- South Africa
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- PATH